Examination of Osteoporosis Treatment for Breast Cancer Treatment-related Bone Loss Evaluation of bone quality by TBS (Trabecular Bone Score)

Examination of Osteoporosis Treatment for Breast Cancer Treatment-related Bone Loss Evaluation of bone quality by TBS (Trabecular Bone Score) - Examination of Osteoporosis Treatment for Breast Cancer Treatment-related Bone Loss Evaluation of bone quality by TBS (Trabecular Bone Score)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040394

Enrollment

Registered

2020-05-20

Start date

2020-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aromatase Inhibitor-Associated Bone Loss in Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Patients who receive breast cancer treatment with aromatase inhibitor at our hospital 2.Treatment of osteoporosis in "Women's HealthCare Outpatient clinic for Breast Cancer Patients" 3.Using Bisphosphonate or denosumab for osteoporosis 4.Osteoporosis treatment has been started and continued with the same drug for more than 1 year

Exclusion criteria

Exclusion criteria: 1.Patients who received continuous administration of osteoporosis before visit "Women's HealthCare Outpatient clinic for Breast Cancer Patients" 2.Has bone metastases 3.changed drug on the way

Design outcomes

Primary

Measure	Time frame
TBS(Trabecular Bone Score) and rate of change before, 6 and 12 months after the start of osteoporosis treatment	—

Secondary

Measure	Time frame
Bone density and bone metabolism markers and rate of change before, 6 and 12 months after the start of osteoporosis treatment	—

Countries

Japan

Contacts

Public ContactEmi Onuma

Yokohama City University Medical Center Department of Gynecology

emionuma@yokohama-cu.ac.jp0452615656

Outcome results